Sarepta Therapeutics (SRPT) EBITDA (2010 - 2026)

Sarepta Therapeutics' EBITDA history runs 17 years deep, the most recent figure standing at $358.4 million for Q1 2026.

• In Q1 2026, EBITDA rose 219.32% year-over-year to $358.4 million; the TTM figure through Mar 2026 stood at -$36.0 million (up 62.36% YoY), while the FY2025 annual figure was -$699.8 million, down 420.88% from the prior year.
• EBITDA was $358.4 million for Q1 2026 at Sarepta Therapeutics, up from -$411.6 million in the prior quarter.
• In the past five years, EBITDA ranged from a high of $358.4 million in Q1 2026 to a low of -$515.5 million in Q1 2023.
• Historically, EBITDA has averaged -$78.6 million across 5 years, with a median of -$40.5 million in 2023.
• Biggest YoY gain for EBITDA was 3115.28% in 2025; the steepest drop was 970.43% in 2025.
• A 5-year view of EBITDA shows it stood at -$107.7 million in 2022, then jumped by 143.83% to $47.2 million in 2023, then surged by 242.46% to $161.7 million in 2024, then slumped by 354.56% to -$411.6 million in 2025, then soared by 187.09% to $358.4 million in 2026.
• The last three EBITDA figures came in at $358.4 million (Q1 2026), -$411.6 million (Q4 2025), and -$179.7 million (Q3 2025), per Business Quant data.